The Adaptive COVID-19 Treatment Trial funded by the National Institute of Allergy and Infectious Disease will set out to determine if treatment with a combination drug therapy consisting of remdesivir and the anti-inflammatory drug baricitinib will be effective and safe for COVID-19 both as a preventive medication as well as disease progression. Another trial is also being planned by biotech firm CytoDyn that would test a combination using remdesivir together with leronlimab.
Trials to assess remdesivir combos to boost efficacy against COVID-19
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.